At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DFTX Definium Therapeutics
Post-Mkt 07-20 18:47:09 EDT
42.80
-1.49
-3.36%
盘后42.83
+0.03+0.07%
18:43 EDT
High45.31Low42.75Vol1.22M
Open43.84D1 Closing44.29Amplitude5.78%
Mkt Cap5.56BTradable Cap5.36BTotal Shares130.00M
T/O53.33MT/O Rate0.98%Tradable Shares125.13M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Definium Therapeutics Issues Options for 30,330 Shares to New Hires Under Inducement Plan
Reuters  ·  04:01
Definium Therapeutics Issues Options for 30,330 Shares to New Hires Under Inducement Plan
Movement Alert｜Definium Therapeutics Rises 5.5% in Regular Trading, DT120 Phase 3 Data and Sector M&A Fuel Momentum
Market Focus  ·  07-16
Movement Alert｜Definium Therapeutics Rises 5.5% in Regular Trading, DT120 Phase 3 Data and Sector M&A Fuel Momentum
S&P 500 Futures Decline in Premarket Trading; Ermenegildo Zegna, JB Hunt Transport Lead
Dow Jones  ·  07-16
S&P 500 Futures Decline in Premarket Trading; Ermenegildo Zegna, JB Hunt Transport Lead
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (gad) Patient Impact and Neurobiology
THOMSON REUTERS  ·  07-16
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (gad) Patient Impact and Neurobiology
Movement Alert｜Definium Therapeutics Rises 5.1% in Pre-Market Trading, DT120 Phase 3 Data and Capital Raise Continue to Fuel Momentum
Market Focus  ·  07-16
Movement Alert｜Definium Therapeutics Rises 5.1% in Pre-Market Trading, DT120 Phase 3 Data and Capital Raise Continue to Fuel Momentum
Movement Alert｜Definium Therapeutics Rises 7.03% Overnight, DT120 Phase 3 Data Momentum Continues
Market Focus  ·  07-16
Movement Alert｜Definium Therapeutics Rises 7.03% Overnight, DT120 Phase 3 Data Momentum Continues
Movement Alert｜Definium Therapeutics Rises 5.04% in After-Hours Trading, Trading at $47.79
Market Focus  ·  07-16
Movement Alert｜Definium Therapeutics Rises 5.04% in After-Hours Trading, Trading at $47.79
Definium Therapeutics (DFTX) Could Be 30% Overvalued After New GAD Study
Simply Wall St.  ·  07-16
Definium Therapeutics (DFTX) Could Be 30% Overvalued After New GAD Study
Will New GAD Treatment Persistence Data Change Definium Therapeutics' (DFTX) Unmet‑Need Narrative?
Simply Wall St.  ·  07-15
Will New GAD Treatment Persistence Data Change Definium Therapeutics' (DFTX) Unmet‑Need Narrative?
Movement Alert｜Definium Therapeutics Rises 5.13% in Regular Trading, Trading at $45.845
Market Focus  ·  07-15
Movement Alert｜Definium Therapeutics Rises 5.13% in Regular Trading, Trading at $45.845
Definium Therapeutics announces results from healthcare claims study in GAD
TIPRANKS  ·  07-14
Definium Therapeutics announces results from healthcare claims study in GAD
Definium Says Claims Study Finds High GAD Drug Discontinuation, Switching Rates
Reuters  ·  07-14
Definium Says Claims Study Finds High GAD Drug Discontinuation, Switching Rates
Movement Alert｜Definium Therapeutics Falls 5.44% in Regular Trading, Trading at $44.45
Market Focus  ·  07-13
Movement Alert｜Definium Therapeutics Falls 5.44% in Regular Trading, Trading at $44.45
Movement Alert｜Definium Therapeutics Falls 5.06% in Regular Trading, Trading at $45.96
Market Focus  ·  07-10
Movement Alert｜Definium Therapeutics Falls 5.06% in Regular Trading, Trading at $45.96
Movement Alert｜Definium Therapeutics Rises 5.09% in Regular Trading, Phase 3 Clinical Success and Major Financing Boost Market Confidence
Market Focus  ·  07-09
Movement Alert｜Definium Therapeutics Rises 5.09% in Regular Trading, Phase 3 Clinical Success and Major Financing Boost Market Confidence
Definium Therapeutics price target raised to $60 from $30 at Stifel
TIPRANKS  ·  07-08
Definium Therapeutics price target raised to $60 from $30 at Stifel
Definium Therapeutics Inc : Stifel Raises Target Price to $60 from $30
THOMSON REUTERS  ·  07-08
Definium Therapeutics Inc : Stifel Raises Target Price to $60 from $30
Definium Therapeutics (DFTX) Following Russell Index Removal And The Fair Value Debate
Simply Wall St.  ·  07-08
Definium Therapeutics (DFTX) Following Russell Index Removal And The Fair Value Debate
Definium Therapeutics Issues Inducement Stock Options for 169,740 Shares to New Hires
Reuters  ·  07-07
Definium Therapeutics Issues Inducement Stock Options for 169,740 Shares to New Hires
LSD Therapy Biotech Definium Fends Off Trade-secret Lawsuit
Reuters  ·  07-02
LSD Therapy Biotech Definium Fends Off Trade-secret Lawsuit

Introduction

Company Name.
Definium Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.
Issue price:
--